Concentra Biosciences LLC, controlled by San Diego's Tang Capital Partners LP, made an unsolicited offer at $3 per share plus ...
As part of an agreement announced two weeks ago, eye-disease-focused Acelyrin was due to be absorbed into immune-mediated ...
Acelyrin earlier this month agreed to an all-stock merger with fellow immune player Alumis, with their combined cash tiding ...
Shares of Acelyrin climbed after the company said it has received an unsolicited indication of interest from Concentra Biosciences for an acquisition at $3 a share. The stock was up 14% at $2.48 in ...
We recently published an article titled Was Jim Cramer Right About These 12 Stocks? In this article, we are going to take a ...
Select Medical Holdings Corporation (NYSE: SEM) Q4 2024 Earnings Call Transcript February 21, 2025 ...
Acelyrin (SLRN) “confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP ...
The drama introduces a potential choice for Acelyrin shareholders: cash now in a deal with Concentra or a potentially bigger return from the all-stock merger with Alumis. Two weeks after Alumis ...
Founder; Select Medical Holdings Corp Martin Jackson; Senior Executive Vice President of Strategic Finance and Operations; Select Medical Holdings Corp Good morning and thank you for joining us today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback